logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10919929 B1

PDFFull Text
Date of Patent:
Feb. 16, 2021

Filed:

Dec. 11, 2014

Glucocorticoid inhibitors for treatment of prostate cancer

Applicant:

Sloan-kettering Institute for Cancer Research, New York, NY (US);

Inventors:

Vivek Arora, New York, NY (US);

Charles L. Sawyers, New York, NY (US);

Michael J. Evans, New York, NY (US);

Darren R. Veach, New York, NY (US);

Assignee:

Sloan-Kettering Institute for Cancer Research, New York, NY (US);

Attorneys:

Choate, Hall & Stewart LLP

Brenda Herschbach Jarrell

Michael A. Shinall

Primary Examiner:

Sabiha N Qazi

Int. Cl.
CPC ...
C07J 17/00 (2006.01); A61K 31/575 (2006.01); A61K 31/58 (2006.01); A61K 31/416 (2006.01); A61K 31/573 (2006.01); A61K 31/7105 (2006.01); A61K 31/4439 (2006.01); A61K 31/4166 (2006.01); A61K 31/5375 (2006.01); A61K 31/713 (2006.01); G01N 33/74 (2006.01); A61K 45/06 (2006.01); C07J 9/00 (2006.01); C07J 43/00 (2006.01);
U.S. Cl.
CPC ...
C07J 17/00 (2013.01); A61K 31/416 (2013.01); A61K 31/4166 (2013.01); A61K 31/4439 (2013.01); A61K 31/5375 (2013.01); A61K 31/573 (2013.01); A61K 31/575 (2013.01); A61K 31/58 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); C07J 9/00 (2013.01); C07J 43/003 (2013.01); G01N 33/743 (2013.01);
Abstract

The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes. The present invention also provides systems for using such agents, for example to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer.

Find Patent Forward Citations

Loading…